Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24665367 | 1.00 | LTA4H (0.38) | LTA4HKCNH2S1PR3FFAR1TRPA1 | |
| SCHEMBL30006188 | 0.90 | LTA4H (0.46) | LTA4HKCNH2FFAR1TRPA1MAPT | |
| SCHEMBL24664144 | 0.90 | LTA4H (0.46) | LTA4HKCNH2FFAR1TRPA1MAPT | |
| SCHEMBL27171436 | 0.90 | GRN (0.42) | FFAR1TRPA1NPSR1PPARGGRN | |
| SCHEMBL27204693 | 0.90 | GRN (0.42) | FFAR1TRPA1NPSR1PPARGGRN | |
| SCHEMBL29123536 | 0.89 | MAPK1 (0.42) | FFAR1MAPT | |
| SCHEMBL24664167 | 0.89 | MAPK1 (0.42) | FFAR1MAPT | |
| SCHEMBL24665373 | 0.89 | LTA4H (0.38) | LTA4HKCNH2FFAR1MAPTPKM | |
| SCHEMBL30005383 | 0.89 | LTA4H (0.38) | LTA4HKCNH2FFAR1MAPTPKM | |
| SCHEMBL24665399 | 0.86 | LTA4H (0.56) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4628163-A1 | NOVEL HETEROARYL AMINOPROPANOL DERIVATIVES | Novartis AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| EP-4323062-B1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2025-07-23 | — | — | EP | disclosed |
| US-20240199593-A1 | Novel Heteroaryl Aminopropanol Derivatives | NOVARTIS PHARMA AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| EP-4323062-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20220348566-A1 | Novel Heteroaryl Aminopropanol Derivatives | NOVARTIS AG (CH) | 2022-11-03 | — | — | US | disclosed |
| WO-2022219546-A1 | HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348566-A1 | Novel Heteroaryl Aminopropanol Derivatives | CYP11B2, CYP11B1, CYP3A43 | LTA4H 953/4885KCNH2 1671/4885S1PR3 830/4885 |
| US-20240199593-A1 | Novel Heteroaryl Aminopropanol Derivatives | CYP3A43, CYP3A5, CYP51A1 | LTA4H 1384/4885KCNH2 3303/4885S1PR3 874/4885 |
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | CYP3A43, CYP11B2, ADRB3 | LTA4H 1006/4885KCNH2 1449/4885S1PR3 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.